Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients aged 1 year old and older, and in adults.
Midostaurin Capsules are indicated to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.
In 2023, total prescription medicine use increased by 3% and reached 210 billion days of therapy, per IQVIA's Use of Medicines in the U.S. 2024 report.